clevegen bexmarilimab new cancer immunotherapy drug development finland faron drug antibody convert immune suppressive tumourassociated macrophages tams immune active microphages potential wide use oncology currently undergoing trials codename matins innovative treatment metastatic inoperable solid tumours cutaneous melanoma hepatobiliaryhepatocellular pancreatic ovarian colorectal cancers host significant number tams represent million cases annually worldwidecitation needed following encouraging results early european trials regarding drugs tolerability safety matins programme extended later trials study drugs efficacy treating patients high occurrence readily identified liquid biopsy using blood myeloid cell staining technique httpsenwikipediaorgwikiclevegen